Thioredoxin-interacting protein and myocardial mitochondrial function in ischemia-reperfusion injury

Trends in Cardiovascular Medicine

Volumn 24, Issue 2, 2014, Pages 75-80

  Yoshioka, Jun ^a   Lee, Richard T ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; THIOREDOXIN; THIOREDOXIN INTERACTING PROTEIN;

ANAEROBIC METABOLISM; BIOENERGY; GLUCOSE TRANSPORT; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC REGULATION; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REPERFUSION INJURY; RESPIRATORY FUNCTION; REVIEW;

ANIMALS; CARRIER PROTEINS; CELL RESPIRATION; ENERGY METABOLISM; GLUCOSE; HUMANS; MITOCHONDRIA, HEART; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; THIOREDOXINS;

EID: 84891919305     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2013.06.007     Document Type: Review

References (37)

1. Aragones J., Schneider M., Van Geyte K., Fraisl P., Dresselaers T., Mazzone M., et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nature Genetics 2008, 40:170-180.
2. Baker A.F., et al. Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas 2008, 36:178-186.
3. Barger P.M., et al. p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor alpha: a potential role in the cardiac metabolic stress response. The Journal of Biological Chemistry 2001, 276:44495-44501.
4. Chen J., et al. Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein. American Journal of Physiology. Endocrinology and Metabolism 2009, 296:E1133-E1139.
5. Chen Q., et al. Modulation of electron transport protects cardiac mitochondria and decreases myocardial injury during ischemia and reperfusion. American Journal of Physiology. Cell Physiology 2007, 292:C137-C147.
6. Chen Q., et al. Blockade of electron transport before cardiac ischemia with the reversible inhibitor amobarbital protects rat heart mitochondria. Journal of Pharmacology and Experimental Therapeutics 2006, 316:200-207.
7. Chen Q., Lesnefsky E.J. "Hiding out" from chronic ischemia with help from the mitochondria?. Journal of Molecular and Cellular Cardiology 2006, 41:956-958.
8. Chen Y., et al. Overexpressed human mitochondrial thioredoxin confers resistance to oxidant-induced apoptosis in human osteosarcoma cells. Journal of Biological Chemistry 2002, 277:33242-33248.
9. Chutkow W.A., et al. Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes 2010, 59:1424-1434.
10. Damdimopoulos A.E., et al. Human mitochondrial thioredoxin. Involvement in mitochondrial membrane potential and cell death. Journal of Biological Chemistry 2002, 277:33249-33257.
11. Duncan J.G., et al. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 2007, 115:909-917.
12. Kelly D.P. Hypoxic reprogramming. Nature Genetics 2008, 40:132-134.
13. Liu G.H., et al. Thioredoxin-mediated negative autoregulation of peroxisome proliferator-activated receptor alpha transcriptional activity. Molecular Biology of the Cell 2006, 17:1822-1833.
14. McLeod C.J., et al. Uncoupling proteins 2 and 3 function in concert to augment tolerance to cardiac ischemia. Journal of Biological Chemistry 2005, 280:33470-33476.
15. Minn A.H., et al. Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 2005, 146:2397-2405.
16. Nadtochiy S.M., et al. Different mechanisms of mitochondrial proton leak in ischaemia/reperfusion injury and preconditioning: implications for pathology and cardioprotection. Biochemical Journal 2006, 395:611-618.
17. Papandreou I., et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metabolism 2006, 3:187-197.
18. Parikh H., et al. TXNIP regulates peripheral glucose metabolism in humans. PLoS Medicine 2007, 4:e158.
19. Patwari P., et al. Thioredoxin-independent regulation of metabolism by the alpha-arrestin proteins. Journal of Biological Chemistry 2009, 284:24996-25003.
20. Saxena G., et al. Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. The Journal of Biological Chemistry 2010, 285:3997-4005.
21. Semenza G.L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. Journal of Applied Physiology 2000, 88:1474-1480.
22. Shalev A., et al. Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway. Endocrinology 2002, 143:3695-3698.
23. Shin D., Jeon J.H., Jeong M., Suh H.W., Kim S., Kim H.C., et al. VDUP1 mediates nuclear export of HIF1alpha via CRM1-dependent pathway. Biochim Biophys Acta 2008, 1783:838-848.
24. Stoltzman C.A., et al. Glucose sensing by MondoA:Mlx complexes: a role for hexokinases and direct regulation of thioredoxin-interacting protein expression. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:6912-6917.
25. Tanaka T., et al. Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. The EMBO Journal 2002, 21:1695-1703.
26. van Greevenbroek M.M., et al. Genetic variation in thioredoxin interacting protein (TXNIP) is associated with hypertriglyceridaemia and blood pressure in diabetes mellitus. Diabetic Medicine 2007, 24:498-504.
27. Wang D., et al. Control of mitochondrial outer membrane permeabilization and Bcl-xL levels by thioredoxin 2 in DT40 cells. Journal of Biological Chemistry 2006, 281:7384-7391.
28. Weissler A.M., et al. Role of anaerobic metabolism in the preservation of functional capacity and structure of anoxic myocardium. Journal of Clinical Investigation 1968, 47:403-416.
29. Welsh S.J., et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Molecular Cancer Therapeutics 2003, 2:235-243.
30. Woodfield S.L., et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. Journal of the American College of Cardiology 1996, 28:1661-1669.
31. Wu N., et al. AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Molecular Cell 2013, 49:1167-1175.
32. Xiang G., et al. Catalytic degradation of vitamin D up-regulated protein 1 mRNA enhances cardiomyocyte survival and prevents left ventricular remodeling after myocardial ischemia. Journal of Biological Chemistry 2005, 280:39394-39402.
33. Yoshioka J., et al. Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. Journal of Clinical Investigation 2012, 122:267-279.
34. Yoshioka J., et al. Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circulation Research 2007, 101:1328-1338.
35. Zhang H., et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007, 11:407-420.
36. Zhang R., et al. Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circulation Research 2004, 94:1483-1491.
37. Zhou J., et al. Thioredoxin 1 and thioredoxin 2 have opposed regulatory functions on hypoxia-inducible factor-1alpha. Journal of Biological Chemistry 2007, 282:7482-7490.